
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No.)

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material under §240.14a-12

AQUESTIVE THERAPEUTICS, INC.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

- No fee required.
 - Fee paid previously with preliminary materials.
 - Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
-
-
-

Your **Vote** Counts!

AQUESTIVE THERAPEUTICS, INC.

2023 Annual Meeting

Vote by June 20, 2023

11:59 PM ET

AQUESTIVE THERAPEUTICS, INC.
30 TECHNOLOGY DRIVE
WARREN, NJ 07059



V15175-P94416

You invested in AQUESTIVE THERAPEUTICS, INC. and it's time to vote!

You have the right to vote on proposals being presented at the 2023 Annual Meeting of Stockholders. **This is an important notice regarding the availability of proxy material for the stockholder meeting to be held on June 21, 2023 at 9:30 AM Eastern Time.**

Get informed before you vote

View the 2023 Proxy Statement and 2022 Annual Report on Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to June 7, 2023. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.



For complete information and to vote, visit www.ProxyVote.com

Control #

Smartphone users

Point your camera here and vote without entering a control number



Vote Virtually at the Meeting*

June 21, 2023
9:30 AM, Eastern Time

Virtually at:
www.virtualshareholdermeeting.com/AQST2023

*Please check the meeting materials for any special requirements for meeting attendance.

THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming stockholder meeting. You are encouraged to access and review the complete proxy materials. Please follow the instructions on the reverse side to access the proxy materials and to vote these important matters.

Voting Items	Board Recommends
1. To elect Gregory B. Brown, M.D. and John S. Cochran as Class II members of the Board of Directors, each to serve for a three-year term until the Company's 2026 Annual Meeting of Stockholders and until his successor is duly elected and qualified. Nominees: 1a) Gregory B. Brown, M.D. 1b) John S. Cochran	✔ For
2. To approve an amendment to the Aquestive Therapeutics, Inc. 2018 Equity Incentive Plan to increase the number of shares of common stock available for issuance under the plan.	✔ For
3. To approve an amendment to the Amended and Restated Certificate of Incorporation to provide for exculpation of officers of the Company as permitted by recent amendments to Delaware law.	✔ For
4. To ratify the appointment of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2023.	✔ For
5. To act upon any other matters that may properly come before the 2023 Annual Meeting or any adjournment or postponement thereof.	

Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Settings".